Latest & greatest articles for budesonide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on budesonide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on budesonide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for budesonide

101. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group.

Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. 11027739 2000 10 12 2000 10 12 2013 11 21 0028-4793 343 15 2000 Oct 12 The New England journal of medicine N. Engl. J. Med. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. 1054-63 Antiinflammatory therapies, such as inhaled corticosteroids or nedocromil, are recommended for children (...) with asthma, although there is limited information on their long-term use. We randomly assigned 1041 children from 5 through 12 years of age with mild-to-moderate asthma to receive 200 microg of budesonide (311 children), 8 mg of nedocromil (312 children), or placebo (418 children) twice daily. We treated the participants for four to six years. All children used albuterol for asthma symptoms. There was no significant difference between either treatment and placebo in the primary outcome, the degree

NEJM2000

102. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children

The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children Barnes N C, Thwaites R M, Price M J Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technologies were the use of fluticasone propionate (FP) and budesonide (Bud) in the treatment of patients suffering from asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of adult

NHS Economic Evaluation Database.1999

103. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial.

Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. 10367823 1999 06 17 1999 06 17 2016 10 17 0098-7484 281 22 1999 Jun 09 JAMA JAMA Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. 2119-26 Relapses of acute asthma following emergency department (ED) discharge can (...) consecutive patients aged 16 to 60 years presented to the ED with acute asthma; after excluding those using oral and/or inhaled corticosteroids as well as those meeting other exclusion criteria, 188 were included in the study. Patients were discharged with a nontapering course of oral prednisone (50 mg/d) for 7 days. In a double-blind fashion, patients were randomly assigned to 1600 microg/d of inhaled budesonide (n = 94) or identical placebo (n = 94) for 21 days. Incidence of relapse, defined

JAMA1999

104. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. 10379018 1999 06 24 1999 06 24 2006 11 15 0028-4793 340 25 1999 Jun 24 The New England journal of medicine N. Engl. J. Med. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study (...) on Chronic Obstructive Pulmonary Disease. 1948-53 Although patients with chronic obstructive pulmonary disease (COPD) should stop smoking, some do not. In a double-blind, placebo-controlled study, we evaluated the effect of the inhaled glucocorticoid budesonide in patients with mild COPD who continued smoking. After a six-month run-in period, we randomly assigned 1277 subjects (mean age, 52 years; mean forced expiratory volume in one second [FEV1], 77 percent of the predicted value; 73 percent men) to twice-daily treatment with 400

NEJM1999

105. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. 10359405 1999 06 24 1999 06 24 2015 06 16 0140-6736 353 9167 1999 May 29 Lancet (London, England) Lancet Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. 1819-23 Little is known about the long-term efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease (COPD). We (...) investigated the efficacy of inhaled budesonide on decline in lung function and respiratory symptoms in a 3-year placebo-controlled study of patients with COPD. We used a parallel-group, randomised, double-blind, placebo-controlled design in a singlecentre study, nested in a continuing epidemiological survey (the Copenhagen City Heart Study). Inclusion criteria were as follows: no asthma; a ratio of forced expiratory volume in 1 s (FEV1) and vital capacity of 0.7 or less; FEV1 which showed no response (<15

Lancet1999

106. Cost-effectiveness of budesonide controlled ileal release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohn's disease in Sweden

Cost-effectiveness of budesonide controlled ileal release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohn's disease in Sweden Cost-effectiveness of budesonide controlled ileal release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohn's disease in Sweden Cost-effectiveness of budesonide controlled ileal release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohn's disease (...) in Sweden Noble I, Brown R, Danielsson A, Ericsson K, Floren C H, Hertzman P, Lofberg R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using budesonide controlled ileal release (CIR) capsules 6mg per day as maintenance therapy

NHS Economic Evaluation Database.1998

107. Cost effectiveness of fluticasone and budesonide in patients with moderate asthma

Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Steinmetz K O, Volmer T, Trautmann M, Kielhorn A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Inhaled fluticasone (metered dose inhaler) was compared to inhaled budesonide (Turbuhaler(R) in corticosteroid-naive patients with moderate asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The authors did not define the study population. The study sample comprised patients enrolled in a multi-centre trial, who were aged between

NHS Economic Evaluation Database.1998

108. A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup.

A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. 9709042 1998 08 20 1998 08 20 2013 11 21 0028-4793 339 8 1998 Aug 20 The New England journal of medicine N. Engl. J. Med. A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. 498-503 In children with croup, treatment with nebulized budesonide decreases symptoms, but it is uncertain how budesonide compares with dexamethasone (...) , the conventional therapy for croup, and whether either reduces the rate of hospitalization. We performed a double-blind, randomized trial involving 144 children with moderately severe croup. The children were treated with racepinephrine and a single dose of 4 mg of nebulized budesonide (48 children), 0.6 mg of intramuscular dexamethasone per kilogram of body weight (47 children), or placebo (49 children). The children were assessed before treatment and then hourly for five hours after treatment. Physicians who

NEJM1998

109. Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial.

Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial. 9613912 1998 06 10 1998 06 10 2016 10 17 0098-7484 279 20 1998 May 27 JAMA JAMA Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial. 1629-32 The effectiveness of glucocorticoids for patients with croup is well established but it remains uncertain which glucocorticoid regimen is most effective. To determine the effectiveness of 3 glucocorticoid regimens (...) in patients with croup. Randomized controlled trial with parallel design. Emergency departments of 2 Canadian pediatric tertiary care hospitals. Children with a clinical syndrome consistent with croup, aged 3 months to 5 years, with a croup score of 2 or greater following at least 15 minutes of mist therapy. Oral dexamethasone, 0.6 mg/kg, and nebulized placebo; oral placebo and nebulized budesonide, 2 mg; or oral dexamethasone, 0.6 mg/kg, and nebulized budesonide, 2 mg. Westley croup score (primary

JAMA1998

110. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. 9691103 1998 08 06 1998 08 06 2013 11 21 0028-4793 339 6 1998 Aug 06 The New England journal of medicine N. Engl. J. Med. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. 370-4 Crohn's disease is often treated with glucocorticoids or mesalamine. We compared the efficacy and safety of controlled-ileal-release (...) budesonide capsules and slow-release mesalamine tablets in patients with active Crohn's disease affecting the ileum, the ascending colon, or both. In a double-blind, multicenter trial, we enrolled 182 patients with scores of 200 to 400 on the Crohn's Disease Activity Index (with higher scores indicating greater disease activity) and randomly assigned 93 to receive 9 mg of budesonide once daily and 89 to receive 2 g of mesalamine twice daily for 16 weeks. The primary efficacy variable was clinical

NEJM1998

111. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. 9358137 1997 11 13 1997 11 13 2015 11 19 0028-4793 337 20 1997 Nov 13 The New England journal of medicine N. Engl. J. Med. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. 1405-11 The role of long-acting, inhaled beta2-agonists (...) in treating asthma is uncertain. In a double-blind study, we evaluated the effects of adding inhaled formoterol to both lower and higher doses of the inhaled glucocorticoid budesonide. After a four-week run-in period of treatment with budesonide (800 microg twice daily), 852 patients being treated with glucocorticoids were randomly assigned to one of four treatments given twice daily by means of a dry-powder inhaler (Turbuhaler): 100 microg of budesonide plus placebo, 100 microg of budesonide plus 12

NEJM1997

112. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma.

A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. 9358138 1997 11 13 1997 11 13 2013 11 21 0028-4793 337 20 1997 Nov 13 The New England journal of medicine N. Engl. J. Med. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. 1412-8 Inhaled glucosteroids and oral theophylline are widely used to treat asthma. We compared the benefits of adding theophylline to inhaled (...) glucosteroid with those of doubling the dose of inhaled glucosteroid in patients with persistent symptoms despite the use of inhaled glucosteroid. In a double-blind, placebo-controlled trial, we randomly assigned 62 patients to receive either 400 microg of inhaled budesonide (low-dose budesonide) with 250 or 375 mg of theophylline (depending on body weight) or 800 microg of inhaled budesonide (high-dose budesonide). All doses were given twice daily for three months. Lung function was measured serially

NEJM1997

113. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma.

Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. 8058076 1994 09 15 1994 09 15 2013 11 21 0028-4793 331 11 1994 Sep 15 The New England journal of medicine N. Engl. J. Med. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. 700-5 In a previous study, we found that two years of treatment with an inhaled corticosteroid, budesonide, was more effective than treatment with an inhaled beta 2-agonist, terbutaline, in patients (...) with newly diagnosed, generally mild asthma. We continued this study for a third year to investigate whether the steroid dose could be reduced or discontinued and what effect crossover of patients from beta 2-agonist therapy to corticosteroid therapy would have. A total of 37 patients treated for two years with inhaled budesonide at a dose of 1200 micrograms per day were randomly assigned to treatment with 400 micrograms of budesonide per day (19 patients) or placebo (18 patients) in a double-blind

NEJM1994

114. Nebulized budesonide for children with mild-to-moderate croup.

Nebulized budesonide for children with mild-to-moderate croup. 8022437 1994 08 04 1994 08 04 2010 03 24 0028-4793 331 5 1994 Aug 04 The New England journal of medicine N. Engl. J. Med. Nebulized budesonide for children with mild-to-moderate croup. 285-9 Although recent evidence has strongly supported the use of glucocorticoid therapy in children hospitalized with croup, the benefit of this therapy in children with less severe croup has not been documented. This randomized, double-blind trial (...) compared a nebulized glucocorticoid, budesonide, with placebo in outpatients with mild-to-moderate croup. Children three months to five years of age were eligible for the study if their croup scores fell in the mild-to-moderate range (scores of 2 to 7 out of a possible 17). The patients were randomly assigned to receive either 2 mg (4 ml) of nebulized budesonide (27 children) or 4 ml of nebulized normal saline (27 children); they were then assessed hourly for up to four hours by investigators who were

NEJM1994

115. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. 8078529 1994 10 06 1994 10 06 2013 11 21 0028-4793 331 13 1994 Sep 29 The New England journal of medicine N. Engl. J. Med. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. 836-41 Corticosteroids are the most efficacious drugs for inducing remission in active Crohn's disease, but their benefits are frequently offset by serious side effects. Budesonide (...) is a corticosteroid with high topical antiinflammatory activity but low systemic activity because of extensive hepatic metabolism. We investigated the efficacy and safety of an oral controlled-ileal-release preparation of budesonide in patients with active Crohn's disease involving the ileum or ileum and proximal colon. In a double-blind, multicenter trial, 258 patients were randomly assigned to receive placebo or one of three doses of budesonide--3, 9, or 15 mg daily. The primary outcome measure was clinical

NEJM1994

116. A comparison of budesonide with prednisolone for active Crohn's disease.

A comparison of budesonide with prednisolone for active Crohn's disease. 8078530 1994 10 06 1994 10 06 2013 11 21 0028-4793 331 13 1994 Sep 29 The New England journal of medicine N. Engl. J. Med. A comparison of budesonide with prednisolone for active Crohn's disease. 842-5 Patients with active Crohn's disease are often treated with corticosteroids, but the treatment has many side effects. Budesonide is a potent, well-absorbed corticosteroid, but because of a high rate of first-pass metabolism (...) in the liver, its systemic bioavailability is low. We conducted a randomized, double-blind, 10-week trial comparing the efficacy and safety of an oral controlled-release form of budesonide with the efficacy and safety of prednisolone in 176 patients with active ileal or ileocecal Crohn's disease (88 patients in each treatment group). The dose of budesonide was 9 mg per day for eight weeks and then 6 mg per day for two weeks. The dose of prednisolone was 40 mg per day for two weeks, after which

NEJM1994

117. Growth of asthmatic children during treatment with budesonide: a double blind trial.

Growth of asthmatic children during treatment with budesonide: a double blind trial. 1878641 1991 10 03 1991 10 03 2010 03 24 0959-8138 303 6795 1991 Jul 20 BMJ (Clinical research ed.) BMJ Growth of asthmatic children during treatment with budesonide: a double blind trial. 163-5 To determine whether the inhaled glucocorticosteroid budesonide has any adverse effect on short term linear growth in children with mild asthma. Outpatient clinic in secondary referral centre. 15 children aged 6-13 (...) years with normal statural growth velocity during the previous year, no signs of puberty, and no use of systemic or topical steroids in the two months before the study. DESIGN OF INTERVENTIONS: Double blind, randomised crossover trial with two active periods in which budesonide was given in divided daily doses of 200 micrograms and 800 micrograms. During run in and two washout periods placebo was given. After the second washout period the children received open treatment with 400 micrograms

BMJ1991 Full Text: Link to full Text with Trip Pro

118. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma.

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. 2062329 1991 08 08 1991 08 08 2015 11 19 0028-4793 325 6 1991 Aug 08 The New England journal of medicine N. Engl. J. Med. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. 388-92 The presence of airway inflammation even in mild asthma points to the potential value of antiinflammatory therapy. We compared the effect (...) of an inhaled corticosteroid, budesonide, with that of an inhaled beta 2-agonist, terbutaline, in the long-term treatment of newly detected asthma. We studied 103 patients (29 male and 74 female patients 15 to 64 years old) in whom asthma had appeared within the previous year. The patients were randomly assigned in blinded fashion to two treatment groups: one to receive 600 micrograms of inhaled budesonide twice a day, and the other to receive 375 micrograms of inhaled terbutaline twice a day. The study

NEJM1991

119. Inhaled budesonide for treatment of recurrent wheezing in early childhood.

Inhaled budesonide for treatment of recurrent wheezing in early childhood. 1975851 1990 10 12 1990 10 12 2015 06 16 0140-6736 336 8716 1990 Sep 15 Lancet (London, England) Lancet Inhaled budesonide for treatment of recurrent wheezing in early childhood. 649-51 77 children, aged 11 to 36 months (mean 24) with moderately severe recurrent wheezing, were treated with budesonide pressurised aerosol 400 micrograms twice daily or placebo for 12 weeks in a double-blind, parallel-group trial. Aerosols (...) were inhaled from a spacer with a facemask. Budesonide significantly improved symptom scores of wheezing, sleep disturbance, and patient happiness. The frequency of severe exacerbations that required a course of oral prednisolone was also significantly reduced. The treatment effect appeared to be fully established after 6-8 weeks and no side-effects could be ascribed to the active treatment. The findings indicate that young children below 3 years of age can inhale a pressurised aerosol from

Lancet1990

120. Controlled trial of budesonide given by the nebuhaler in preschool children with asthma.

Controlled trial of budesonide given by the nebuhaler in preschool children with asthma. 3044506 1988 10 05 1988 10 05 2013 10 01 0959-8138 297 6642 1988 Jul 16 BMJ (Clinical research ed.) BMJ Controlled trial of budesonide given by the nebuhaler in preschool children with asthma. 163-6 To determine whether the inhaled corticosteroid budesonide, given by a Nebuhaler spacing device, was effective in prophylaxis of asthma in preschool children. Double blind, placebo controlled, random order (...) crossover trial with two week practice run in period. Outpatient clinic referrals in secondary referral centre. 39 children aged 2-6 years selected for the following: able to use Nebuhaler; parents able to complete record card; poorly controlled asthma (defined); not already on systemic or inhaled steroids. Eleven withdrew for various reasons not connected with intolerance to budesonide. Age, sex, other atopies, and symptoms during run in period were similar in the 28 children who completed the trial

BMJ1988 Full Text: Link to full Text with Trip Pro